Raptor Pharmaceutical Corp. Coverage Initiated by Analysts at FBR Capital Markets (RPTP)
Equities research analysts at FBR Capital Markets initiated coverage on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $17.00 price target on the stock. FBR Capital Markets’ target price would indicate a potential upside of 15.33% from the stock’s previous close.
RPTP has been the subject of a number of other recent research reports. Analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. from $14.00 to $17.00 in a research note to investors on Tuesday, October 29th. They now have an “outperform” rating on the stock. Separately, analysts at Oppenheimer downgraded shares of Raptor Pharmaceutical Corp. from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, September 25th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $13.29.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 14.74 on Wednesday. Raptor Pharmaceutical Corp. has a 52-week low of $4.35 and a 52-week high of $15.29. The stock’s 50-day moving average is $14.31 and its 200-day moving average is $10.49. The company’s market cap is $879.3 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.30) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.30). Analysts expect that Raptor Pharmaceutical Corp. will post $-1.23 EPS for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.